Occurrence of β-blockers and β-agonists in hospital effluents and their receiving rivers in southern Taiwan

Desalination and Water Treatment

Volumn 32, Issue 1-3, 2011, Pages 49-56

  Yu, Tsung Hsien ^a   Lin, Angela Yu Chen ^a   Wang, Xiao Huan ^a   Lin, Cheng Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Liquid chromatography tandem mass spectroscopy; Pharmaceuticals; Solid phase extraction; agonists; blockers

Indexed keywords

ANIMALIA;

EID: 80052894100     PISSN: 19443994     EISSN: 19443986     Source Type: Journal    
DOI: 10.5004/dwt.2011.2677     Document Type: Article

References (23)

1. D.W. Kolpin, E.T. Furlong, M.T. Meyer, E.M. Thurman, S.D. Zaugg, L.B. Barber and H.T. Buxton, Pharmaceuticals, hormones, and other organic wastewater contaminants in US streams, 1999-2000: A national reconnaissance, Environ. Sci. Technol., 36 (2002) 1202-1211.
2. A.Y.C. Lin and Y.T. Tsai, Occurrence of pharmaceuticals in Taiwan's surface waters: Impact of waste streams from hospitals and pharmaceutical production facilities, Sci. Total Environ., 407 (2009) 3793-3802.
3. A.Y.-C. Lin, T.-H. Yu and C.-F. Lin, Pharmaceutical contamination in residential, industrial, and agricultural waste streams: Risk to aqueous environments in Taiwan, Chemosphere, 74 (2008) 131-141.
4. B. Ferrari, R. Mons, B. Vollat, B. Fraysse, N. Paxeus, R. Lo Giudice, A. Pollio and J. Garric, Environmental risk assessment of six human pharmaceuticals: Are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment?, Environ. Toxicol. Chem., 23 (2004) 1344-1354.
5. D.B. Huggett, B.W. Brooks, B. Peterson, C.M. Foran and D. Schlenk, Toxicity of select beta adrenergic receptor-blocking pharmaceuticals (b-blockers) on aquatic organisms, Arch. Environ. Con. Tox., 43 (2002) 229-235.
6. O.V. Martin and N. Voulvoulis, Sustainable risk management of emerging contaminants in municipal wastewaters, Philos. T. R. Soc. A., 367 (2009) 3895-3922.
7. A.Y.-C. Lin, T.-H. Yu and S.K. Lateef, Removal of pharmaceuticals in secondary wastewater treatment processes in Taiwan, J. Hazard. Mater., 167 (2009) 1163-1169.
8. M.J. Gómez, M. Petrovic, A.R. Fernandez-Alba and D. Barcelo, Determination of pharmaceuticals of various therapeutic classes by solid-phase extraction and liquid chromatography-tandem mass spectrometry analysis in hospital effluent wastewaters, J. Chromatogr. A, 1114 (2006) 224-233.
9. N. Vieno, T. Tuhkanen and L. Kronberg, Elimination of pharmaceuticals in sewage treatment plants in Finland, Water Res., 41 (2007) 1001-1012.
10. B. Kasprzyk-Hordern, R.M. Dinsdale and A.J. Guwy, The removal of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs during wastewater treatment and its impact on the quality of receiving waters, Water Res., 43 (2009) 363-380.
11. M. Gros, M. Petrovic and D. Barcelo, Wastewater treatment plants as a pathway for aquatic contamination by pharmaceuticals in the ebro river basin (northeast spain), Environ. Toxicol. Chem., 26 (2007) 1553-1562.
12. Water Resources Agency, in, Ministry of Economic Affairs, Taiwan.
13. Bureau of National Health Insurance, Taiwan, 2008.
14. J. Blanca, P. Munoz, M. Morgado, N. Mendez, A. Aranda, T. Reuvers and H. Hooghuis, Determination of clenbuterol, ractopamine and zilpaterol in liver and urine by liquid chromatography tandem mass spectrometry, Anal. Chim. Acta., 529 (2005) 199-205.
15. N.M. Vieno, T. Tuhkanen and L. Kronberg, Analysis of neutral and basic pharmaceuticals in sewage treatment plants and inrecipient rivers using solid phase extraction and liquid chromatography-tandem mass spectrometry detection, J. Chromatogr. A, 1134 (2006) 101-111.
16. L.D. Williams, M.I. Churchwell and D.R. Doerge, Multiresidue confirmation of [beta]-agonists in bovine retina and liver using LC-ES/MS/MS, J. Chromatogr. B, 813 (2004) 35-45.
17. M. Gros, M. Petrovic and D. Barcel, Development of a multi-residue analytical methodology based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for screening and trace level determination of pharmaceuticals in surface and wastewaters, Talanta, 70 (2006) 678-690.
18. D. Bendz, N.A. Paxeus, T.R. Ginn and F.J. Loge, Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Hoje River in Sweden, J. Hazard. Mater., 122 (2005) 195-204.
19. D. Calamari, E. Zuccato, S. Castiglioni, R. Bagnati and R. Fanelli, Strategic survey of therapeutic drugs in the Rivers Po and Lambro in northern Italy, Environ. Sci. Technol., 37 (2003) 1241-1248.
20. B. Kasprzyk-Hordern, R.M. Dinsdale and A.J. Guwy, Multi-residue method for the determination of basic/neutral pharmaceuticals and illicit drugs in surface water by solid-phase extraction and ultra performance liquid chromatography-positive electrospray ionisation tandem mass spectrometry, J. Chromatogr. A, 1161 (2007) 132-145.
21. C. Carlsson, A.K. Johansson, G. Alvan, K. Bergman and T. Kuhler, Are pharmaceuticals potent environmental pollutants? Part I: Environmental risk assessments of selected active pharmaceutical ingredients, Sci. Total Environ., 364 (2006) 67-87.
22. M. Cleuvers, Initial risk assessment for three beta-blockers found in the aquatic environment, Chemosphere, 59 (2005) 199-205.
23. O.A.H. Jones, N. Voulvoulis and J.N. Lester, Aquatic environmental assessment of the top 25 English prescription pharmaceuticals, Water Res., 36 (2002) 5013-5022.